In today’s Pharmaceutical Executive Daily, we cover Biogen’s acquisition of Alcyone Therapeutics to expand its drug delivery ...

FDA denies approval for Rexulti in PTSD treatment, citing insufficient evidence despite clinical trials. Otsuka and Lundbeck plan next steps.

Pfizer acquires Metsera for $4.9 billion, enhancing its portfolio in obesity and cardiovascular treatments with innovative ...

Peter Rubin discusses how the industry is an ecosystem and each of the parts will feel the impact differently.

Rob DeWig, VP of Healthcare Sales at Inmar, touches on how access to 25% of benchmarking data from national pharmacy claims ...

Ryan Quigley, CEO of Inizio, explains how AI, personalized medicine, and GLP 1s are shaping commercialization trends.

CDC vaccine advisers delay Hepatitis B schedule changes while recommending separate vaccines for measles, mumps, rubella, and ...

Biogen expands its drug delivery solutions by acquiring Alcyone Therapeutics, enhancing patient-centered therapies with the ...

The FDA has expanded the indication of Incyte’s Opzelura (ruxolitinib) cream to include children aged two to 11 years with ...

VectorY Therapeutics partners with Shape Therapeutics to advance innovative therapies for neurodegenerative diseases using ...

Jason O’Neill, author of 'The Secrets of Successful Drug Launches' and former Dendreon CEO, details how products having an insufficient relative advantage, enter the market too late, or are ...

Rob DeWig, VP of Healthcare Sales at Inmar, touches on looming DSCSA enforcement and the impact of Inmar's reconciliation tools.